Decoy Therapeutics Inc. Cash Flow Conversion Efficiency
Decoy Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has a cash flow conversion efficiency ratio of -0.614x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.65 Million) by net assets ($4.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Decoy Therapeutics Inc. (2014–2025)
Cash flow conversion efficiency of Decoy Therapeutics Inc. from 2014 to 2025. This chart illustrates how Decoy Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Decoy Therapeutics Inc. stock price for real-time trading data and today's change.
Decoy Therapeutics Inc. Cash Flow Conversion Ratio Explained
Decoy Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Decoy Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Decoy Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see DCOY market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Darmi Bersaudara Tbk PT
JK:KAYU
|
0.001x |
|
Greencastle Resources Ltd.
V:VGN
|
-0.014x |
|
Silver Spruce Resources Inc
V:SSE
|
0.000x |
|
Diagonal Bio AB
ST:DIABIO
|
-0.084x |
|
Jubilee Platinum
LSE:JLP
|
0.028x |
|
Tower Investments SA
WAR:TOW
|
-0.116x |
|
Cell Impact AB
ST:CI
|
-0.104x |
|
SolarWorld Aktiengesellschaft
HM:SWVK
|
N/A |
Annual Cash Flow Conversion Efficiency for Decoy Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Decoy Therapeutics Inc. from 2014 to 2025. Review Decoy Therapeutics Inc. (DCOY) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.89 Million | $-4.83 Million | -0.820x | +72.62% |
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -121.23% |
| 2014-12-31 | $-6.54 Million | $-6.93 Million | 1.060x | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more